REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

04 مايو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners

19 أبريل 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021

22 مارس 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences in March

02 مارس 2021 16:16:51 بحسب Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

10 فبراير 2021 15:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

12 يناير 2021 07:30:00 بحسب Nasdaq GlobeNewswire